Skip to main content

Profile hero

Profile details

About Dr. Philipp Dohnke

Philipp is a member of our intellectual property and information technology team.

Since joining the firm, he has worked across many industries with a particular focus on life science and technologies. Philipp has broad expertise in complex, high-profile transactions, including large carve-out and asset deal projects. In addition, Philipp is experienced in drafting and negotiating complex commercial contracts.

He speaks German and English.

Recent work

  • Thermo Fisher on its €725m acquisition of the viral vector manufacturing business of Novasep (Belgium)
  • AstraZeneca on its $39bn acquisition of Alexion Pharmaceuticals
  • Charterhouse / Serb on the $800m acquisition of the BTG Specialty Pharmaceuticals business from Boston Scientific Corporation
  • Novartis on its $5.2bn acquisition of pharmaceutical product Xiidra from Takeda/Shire
  • Merck on its €3.4bn carve-out und sale of its consumer health business to Procter & Gamble
  • Boehringer Ingelheim on its €18bn business swap with Sanofi (Consumer Healthcare against Animal Health)
  • Boehringer Ingelheim on its sale of rights in the pharmaceutical product Buscopan in Brazil to Hypera
  • AstraZeneca / MedImmune on the acquisition of Definiens AG
  • BioNTech on license deals and other collaborations in the field of mRNA products / individualized medicines (including with Pfizer, Genentech, Sanofi, Eli Lilly, Bayer Animal Health and Genmab)
  • Advent International on the $1.9bn acquisition of Sanofi's generics business (Zentiva) and on the add-on acquisition of Alvogen's CEE business
  • Bridgepoint on the acquisition of Pharmazell (manufacturer of active pharmaceutical ingredients)
  • BC Partners on the €2.6bn acquisition of CeramTec
  • BC Partners on the acquisition of a majority stake in the Greek generics company Pharmathen
  • Charterhouse / Cooper on the acquisition of a consumer health product portfolio from Sanofi
  • Charterhouse / Serb on the acquisition of rights in a pharmaceutical product from a US biotech company
  • CVC on the acquisition of a 50% stake in the pharmaceutical excipient manufacturer DFE Pharma from Fonterra (Joint Venture with FrieslandCampina)
  • Qatar Investment Authority on an investment in the German biotech company CureVac
  • Airbus on a joint venture with Bombardier regarding the aircraft program "C Series" (now "A220") and on the subsequent exit of Bombardier from the joint venture
  • ABB on the carve-out and sale of its cable business to NKT
  • Cinven/Hotelbeds on the acquisition of the Global Travel Distribution business from Kuoni
  • Continental on the carve-out of its powertrain business ("Vitesco Technologies")
  • Deutsche Bank on the carve-out and listing of its Asset Management business ("DWS")
  • H.I.G. on the carve-out and acquisition of the European polyutherane "system house" business from Covestro
  • Hellman & Friedman on its €2.9bn acquisition of the internet platforms AutoScout24, FinanceScout24 und Finanzcheck



  • Bucerius Law School, Hamburg, Germany, and Université de Paris I (Panthéon-Sorbonne), France (law)
  • Bucerius Law School, Hamburg, Germany (doctorate in law)
  • Traineeship (Referendariat) at the Higher Regional Court of Hamburg, Germany

Professional memberships

  • German Association for the Protection of Intellectual Property


  • Philipp Dohnke, 2013 Vorfeldschutz im Immaterialgüterrecht